NovoCure (NVCR) Wells Fargo 21st Annual Healthcare Conference summary

Commercial launch and product performance

• Optune Pax launched for stage III pancreatic cancer, with strong initial uptake and about 285 active patients by end of Q2, exceeding expectations for prescriber and patient numbers.

• Approximately 70% of prescriptions are currently converting to active patients, with ongoing efforts to consolidate prescriber interest and expand multi-prescriber engagement.

• Competitive dynamics from new KRAS inhibitors like adagrasib are recognized, but differentiation in patient population and therapy line supports continued momentum.

• Revenue guidance for new indications incorporates competitive factors, with early payer coverage secured and confidence in achieving targets.

• Approval in Europe and anticipated approval in Japan by year-end, with national reimbursement expected in Japan in the first half of next year.

Pipeline and clinical development

• A clinical trial combining Optune Pax with adagrasib is planned, with protocol updates underway and FDA submission expected soon; launch could occur early next year.

• Optune Maia for brain metastases from NSCLC showed doubled time to intracranial progression in trials and is expected to receive FDA approval by year-end.

• Strong clinical interest for Optune Maia, already reflected in NCCN guidelines, but payer acceptance is a key hurdle for commercial ramp.

Market expansion and reimbursement

• U.S. and Japan are key growth markets, with Japan's higher pancreatic cancer incidence expected to drive significant expansion.

• Private payer coverage for Optune Pax is ahead of schedule; broad-based reimbursement typically takes 1–2 years post-launch, with NCCN guideline inclusion as a major milestone.

• European label for Optune Pax differs technically from the U.S., but patient selection and adoption are expected to be similar.